C. difficile: Early and Accurate Detection
Among the wide range of gastrointestinal pathogens that pose significant challenges to laboratories, Clostridioides difficile (C. difficile) plays a particularly important role. Early diagnosis is essential to ensure rapid treatment of affected patients, interrupt transmission chains, and reduce the impact of this significant pathogen on public health. R-Biopharm offers the right solutions for an efficient testing strategy.
A Multi-Step Diagnostic Approach: The Method of Choice
The multi-step diagnostic approach combines high sensitivity and specificity, enabling the distinction between simple colonization and a clinically relevant, toxin-mediated infection. As a result, false-positive findings can be reduced, unnecessary treatments can be avoided, and patients with a true C. difficile infection can be identified reliably.
R-Biopharm Portfolio for C. difficile Diagnostics
- GDH Detection (EIA):
- RIDASCREEN® Clostridium difficile GDH
- RIDA®QUICK Clostridium difficile GDH
- Toxin Detection (EIA):
- RIDASCREEN® Clostridium difficile Toxin A/B
- RIDA®QUICK Clostridium difficile Toxin A/B
- Molecular Diagnostics (NAT/PCR):
- RIDA®UNITY C. difficile
- Vivalytic C. difficile
- RIDA®Plex Faecal Pathogens M
Benefit from the Optimal Combination of the Methods
- Reduction of redundant stool examinations
- Earlier initiation of targeted therapy in patients with CDI (C. difficile infection)
- Less empirical antibiotic treatment in non-CDI patients
- Reduction of unnecessary isolation measures and isolation days
Discover the breadth of the R-Biopharm portfolio and explore the right solutions for the diagnosis of gastrointestinal infections. Gastrointestinal infections: Modern solutions for infection diagnostics
